TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes
Xiaohong Cen(Guangdong Pharmaceutical University), Kui Cheng(Southern Medical University), Jiayin Guo(Guangdong Pharmaceutical University), Kutty Selva Nandakumar(Southern Medical University), Jiabing Jin(Guangdong Pharmaceutical University), Junjie Yang(East China Normal University), Wei Yang(Shenzhen Institutes of Advanced Technology), Shuwen Liu(Zhengzhou University), Gengzhen Zhu(Guangdong Pharmaceutical University), Jianjun Yang(Guangdong Pharmaceutical University), Hang Yin(Cornell University)
Cited by 65
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Evidence that opioids may have toll-like receptor 4 and MD-2 effects
|Brain Behavior and Immunity|2009|574
Morphine activates neuroinflammation in a manner parallel to endotoxin
|Proceedings of the National Academy of Sciences|2012|512
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
|Angewandte Chemie International Edition|2005|449